Real-world data on semaglutide weight loss in 35,000 adults
NCT ID NCT07627074
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines weight loss in adults who took semaglutide (a prescription weight management drug) as part of their routine care. Researchers will analyze medical records from about 35,000 people with overweight or obesity to see how much weight they lost and whether they achieved meaningful reductions. The goal is to understand how effective semaglutide is outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide
What this could lead to
If successful, this study could confirm how well semaglutide works for weight loss in everyday settings, supporting its use for obesity management.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection or adherence. It cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Novo Nordisk Investigational Site
RECRUITINGSeattle, Washington, 98039, United States
-
Novo Nordisk Investigational Site
RECRUITINGLondon, United Kingdom